Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02113631 · ClinicalTrials.gov registry record · NA
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
A NA study, sponsored by Louis Stokes VA Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT02113631 is a NA study that has completed, run by Louis Stokes VA Medical Center. The registered enrollment target is 50 participants.
The verdict
NCT02113631, a NA study, has completed, sponsored by Louis Stokes VA Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
1. The primary objective is to study the comparative effectiveness and tolerability of boceprevir vs. telaprevir in HCV treatment, within the VA population. 2. The secondary objective: * Resource use: recording of differences in resource use, such as direct costs (e.g., drug acquisition costs) and other indirect cost (e.g., staff utilization etc.) as the study will not only derive data by comparing those two drugs but also study the effect on different treatment lengths.
Interventions
- DRUG Peg-IFN
- DRUG Ribavirin
- DRUG Telaprevir
- DRUG Boceprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02113631
The ClinicalTrials.gov registry entry for NCT02113631 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Louis Stokes VA Medical Center, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Peg-IFN is the first listed.
NCT02113631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02113631 about?
NCT02113631 is a clinical study titled "Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir". 1. The primary objective is to study the comparative effectiveness and tolerability of boceprevir vs. telaprevir in HCV treatment, within the VA population. 2. The secondary objective: * Resource use: recording of differences in resource use, such as direct costs (e.g., drug acquisition costs) a...
What is the current status of trial NCT02113631?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2011-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT02113631?
The interventions under investigation include: Peg-IFN (DRUG), Ribavirin (DRUG), Telaprevir (DRUG), Boceprevir (DRUG).
Who is sponsoring clinical trial NCT02113631?
This trial is sponsored by Louis Stokes VA Medical Center, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.